OSRH

Healthcare

OSR Holdings, Inc.

Biotechnology

$0.52Prev. Close
$0.58
+0.07 (+12.72%)Pre-Market
$0.58+12.72%
Feb 6Feb 10Feb 12Feb 17Feb 19Feb 23Feb 26Mar 2Mar 4Mar 6Mar 10Mar 12Mar 16Mar 18Mar 23Mar 26Mar 31Apr 2Apr 7Apr 9Apr 13Apr 15Apr 17Apr 21Apr 23Apr 27Apr 29May 1May 6$0$0$1$1
Key events (≥5% daily moves)
Up dayDown day
About This Company

OSR Holdings, Inc. is a special type of company known as a "blank check company." This means it doesn't currently have its own business operations or products. Instead, OSRH was created with the sole purpose of finding and acquiring another existing company. Its goal is to merge with or buy out one or more businesses, essentially giving that acquired company a public stock listing.

https://www.osr-holdings.com
Key Statistics
Open$0.53
Day High$0.58
Day Low$0.52
Prev. Close$0.52
$1.79
$0.38
$14.99M
3.29M
0.59
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
19
Country
US
IPO Date
2023-03-21
Exchange
NASDAQ
$0.38
52W Low
$0.58
Current
$1.79
52W High
Catalysts & Risks
Catalysts
  • Positive clinical trial results for lead drug candidates, particularly advancing to later stages (e.g., Phase 3) or achieving primary endpoints.
  • Successful regulatory approval (e.g., FDA, EMA) for one or more of its pipeline products, leading to market entry.
  • Strategic partnerships or licensing agreements with larger pharmaceutical companies, providing funding, development expertise, or broader market access.
  • Expansion of intellectual property portfolio through new patent grants or successful defense of existing patents, strengthening market exclusivity.
Risks
  • Failure in clinical trials (e.g., lack of efficacy, significant adverse events), leading to delays or discontinuation of drug development programs.
  • Regulatory hurdles, including denial of approval or requests for additional trials, prolonging time to market and increasing costs.
  • Intense competition from larger, well-funded pharmaceutical companies or other biotech firms developing similar therapies.
  • Dependence on external funding to support research and development, with potential for dilutive financing or inability to secure necessary capital.

AI-generated · For informational use only

Own this stock?

Add it to your portfolio to track your performance.